Collection of Clinical Material in Muscle Invasive Bladder Cancer v2.1

• Research type

  Research Tissue Bank

• IRAS ID

  162506

• Contact name

  R Huddart

• Research summary

  CoMB: Collection of Clinical Material for Molecular Stratification in Patients with Muscle Invasive Bladder Cancer

• REC name

  London - Fulham Research Ethics Committee

• REC reference

  15/LO/0998

• Date of REC Opinion

  30 Jun 2015

• REC opinion

  Further Information Favourable Opinion

• Data collection arrangements

  To store tissue, blood and urine samples from patients with muscle invasive bladder cancer. We will also record each patient's clinical progress from diagnosis so that an individual's laboratory results can be linked to what actually happened to the individual. This collection of samples and data will be used in research studying bladder cancer at a molecular level.

  Patients with bladder cancer routinely attending clinic will be invited to take part. Blood samples will be taken at the same time as routine bloods and so there will be no extra needles or hospital visits for those taking part. Urine samples will also only be taken at routine appointments. Most patients will have had a bladder cancer tissue sample taken at a different hospital at the time of diagnosis. We will ask permission to collect the excess tissue from this sample for storage in our collection, and will also ask for permission to store any excess tissue from future procedures that may be necessary as part of the patient's treatment.

  Blood, urine and tissue samples will be stored in the Royal Marsden Hospital Biobank in Sutton. Clinical information will be stored on a secure database within the Royal Marsden Hospital.

• Research programme

  Bladder cancer can be very unpredictable and it is not clear why patients who appear to have the same type of bladder cancer tumour can respond very differently to the same treatment. In order to try and understand why this is, we need to study bladder cancer at a molecular level. This will allow us to develop ways to tailor a patient's treatment more precisely to their tumour, so called personalised medicine. By better understanding bladder cancer, we can improve outcomes to treatment and may be able to identify new possible treatments. This collection of samples and data will be used in current planned, and future as yet unplanned, bladder cancer research looking to answer this question. We will initially be looking at whether gene patterns at diagnosis can allow us to predict whether or not a patient will respond to radiotherapy for their bladder cancer, and whether genetic abnormalities in the tumour's DNA are predictive of treatment response or outcome.

• Storage license

  30000

• RTBTitle

  CoMB: Collection of Clinical Material for Molecular Stratification in Patients with Muscle Invasive Bladder Cancer

• Establishment organisation

  The Royal Marsden NHS Foundation Trust

• Establishment organisation address

  Downs Road

  Sutton

  SM2 5PT